Poisoning Treatment — Emergency Management & Antidote Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Acute poisoning is a life-threatening medical emergency requiring rapid, systematic assessment and targeted intervention. In the United Kingdom, the National Poisons Information Service (NPIS) and its clinical decision-support database TOXBASE serve as the primary reference for emergency physicians and toxicologists, offering real-time guidance on thousands of substances. Globally, regional poison control centres provide 24-hour clinical support.

The cornerstone of initial management is the structured ABCDE (Airway, Breathing, Circulation, Disability, Exposure) assessment, which must be completed before any specific antidote therapy is initiated. Resuscitation takes absolute priority over decontamination. Simultaneous with stabilisation, clinicians should attempt to identify the substance involved through history, witness accounts, toxidrome recognition, and available containers.

Toxidrome recognition — identifying constellations of clinical signs — allows early empirical treatment even when the exact substance is unknown. The major toxidromes include:

• Sympathomimetic: Tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis (cocaine, amphetamines)
• Anticholinergic: Dry flushed skin, tachycardia, urinary retention, confusion, mydriasis (antihistamines, TCAs)
• Cholinergic (SLUDGE/DUMBELS): Salivation, lacrimation, urination, defaecation, miosis, bronchospasm (organophosphates, carbamates)
• Opioid: Miosis, respiratory depression, reduced consciousness (heroin, morphine, fentanyl)
• Sedative-hypnotic: CNS depression, respiratory depression, normal pupils (benzodiazepines, barbiturates, GHB)
• Serotonin syndrome: Hyperthermia, clonus, agitation, diaphoresis (SSRIs, MAOIs, tramadol combinations)

Early involvement of a clinical toxicologist or poison information service is strongly recommended for all but the most straightforward presentations. Documentation of the time of ingestion, substance, quantity, and any co-ingestants is critical for guiding decontamination and antidote decisions.

Emergency toxicology manages an extremely broad spectrum of poisoning presentations. The most clinically significant categories include:

• Pharmaceutical overdose: Paracetamol (acetaminophen), salicylates, opioids, benzodiazepines, antidepressants (TCAs, SSRIs, SNRIs), antiepileptics, cardiovascular agents (beta-blockers, calcium channel blockers, digoxin), anticoagulants, lithium, iron, and metformin
• Recreational and illicit substances: Cocaine, amphetamines, MDMA, cannabis, GHB, novel psychoactive substances (NPS), synthetic opioids (fentanyl analogues)
• Industrial and household chemicals: Organophosphate and carbamate pesticides, carbon monoxide, cyanide, methanol, ethylene glycol, corrosives (acids and alkalis), hydrocarbons
• Natural toxins: Mushroom poisoning (Amanita phalloides — amatoxin), plant toxins (colchicine, digoxin glycosides from foxglove), snake and spider envenomation
• Environmental toxins: Heavy metals (lead, mercury, arsenic, thallium), radiation exposure

Paracetamol overdose is the single most common cause of acute liver failure in the UK and many Western countries. Opioid toxicity — including from illicitly manufactured fentanyl — represents the most rapidly growing cause of poisoning death globally. Organophosphate poisoning remains a major cause of poisoning mortality in agricultural regions of South and South-East Asia.

Each substance class has a distinct mechanism of toxicity, time course, and treatment algorithm. Carbon monoxide poisoning, often silent in presentation, requires a high index of suspicion in multiple victims from enclosed spaces. Cyanide toxicity from smoke inhalation should be considered alongside CO in victims of house fires with cardiovascular collapse.

Any patient with a known or suspected significant toxic exposure warrants emergency evaluation. Specific indications for immediate hospital attendance include:

• Intentional self-poisoning with any substance, regardless of apparent quantity
• Unintentional ingestion of substances with narrow therapeutic indices (paracetamol, lithium, digoxin, anticoagulants, iron)
• Ingestion of any unknown substance
• Clinical toxidrome features on presentation — altered consciousness, abnormal vital signs, seizures, or dysrhythmias
• Paediatric ingestion of any potentially toxic household product or medication
• Exposure to organophosphates, carbon monoxide, cyanide, methanol, or ethylene glycol
• Envenomation by snake, spider, scorpion, or marine creature

Risk stratification guides the intensity of monitoring and the need for ICU admission. The TOXBASE entry for each specific agent provides recommended observation periods. For paracetamol, the Rumack-Matthew nomogram (plotting plasma paracetamol concentration against time post-ingestion) determines the need for N-acetylcysteine treatment. Results should not be interpreted before 4 hours post-ingestion.

Psychiatric assessment is mandatory for all intentional self-poisoning cases prior to discharge. Patients who require ICU-level care include those with haemodynamic instability, respiratory failure, seizures refractory to initial treatment, severe metabolic acidosis, or ingestion of agents requiring organ support (e.g., methanol, ethylene glycol, certain mushroom toxins). Children and pregnant women require specialist review for most toxic exposures.

Gastrointestinal Decontamination: Activated charcoal (AC) at 1 g/kg body weight (adult dose 50 g) is the primary GI decontamination agent when given within 1 hour of a significant ingestion of an adsorbable substance. Contraindications include unprotected airway, absent gag reflex, corrosive ingestion, and hydrocarbon ingestion. The American Academy of Clinical Toxicology (AACT) and European Association of Poison Centres and Clinical Toxicologists (EAPCCT) do not recommend routine gastric lavage; it may be considered within 1 hour only for life-threatening ingestions of agents not adsorbed by charcoal. Whole bowel irrigation (polyethylene glycol solution 2 L/hour) is used for body packers, iron, and sustained-release formulations.

Specific Antidotes and Management Protocols:

• Paracetamol overdose: N-acetylcysteine (NAC) according to the Prescribing Information nomogram (UK: 21-hour intravenous protocol — 150 mg/kg over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h). Assess risk using plasma paracetamol at 4 hours on the Rumack-Matthew treatment line. Consider extended treatment for staggered overdose or patients with risk factors (alcoholism, malnutrition, enzyme-inducing drugs). Monitor LFTs, creatinine, INR, and acid-base status.
• Opioid toxicity: Naloxone 0.4–2 mg IV/IM/intranasal, titrated to restore adequate spontaneous ventilation (not full alertness — risks acute withdrawal and agitation). Repeat doses or infusion (two-thirds of effective bolus per hour) needed for long-acting opioids (methadone, sustained-release morphine).
• Benzodiazepine toxicity: Supportive care is first line. Flumazenil is a competitive GABA-A antagonist — use with extreme caution: contraindicated in chronic benzodiazepine users (precipitates seizures), TCA co-ingestion (lowers seizure threshold), and epilepsy. Reserved for procedural reversal by anaesthetists.
• Tricyclic antidepressant (TCA) toxicity: Sodium bicarbonate 1–2 mmol/kg IV bolus for QRS >120ms, dysrhythmias, or hypotension — alkalinisation sequesters the drug from sodium channels. Target arterial pH 7.45–7.55. Intralipid emulsion therapy is a second-line option for refractory cardiovascular collapse.
• Organophosphate poisoning: Atropine (titrated to dry secretions, not tachycardia) plus pralidoxime (2-PAM) for reactivation of cholinesterase if given early (before ageing of enzyme-inhibitor bond).
• Carbon monoxide: 100% high-flow oxygen via non-rebreather mask; consider hyperbaric oxygen (HBO) for carboxyhaemoglobin >25%, loss of consciousness, cardiac involvement, or pregnant patients.
• Cyanide: Hydroxocobalamin 5 g IV (preferred) or dicobalt edetate in confirmed symptomatic cases.

Extracorporeal Elimination — Haemodialysis Indications: Haemodialysis (HD) significantly enhances elimination of methanol, ethylene glycol, lithium, and salicylate. Continuous renal replacement therapy (CRRT) is an alternative when HD is not immediately available. HD is indicated in methanol/ethylene glycol toxicity with severe metabolic acidosis (pH <7.1), visual toxicity (methanol), or renal failure; in lithium toxicity with severe neurological features or plasma level >4 mmol/L; and in salicylate toxicity with level >700 mg/L (adult), renal failure, pulmonary oedema, or neurological features.

Timely, protocol-driven management of acute poisoning produces significant reductions in morbidity and mortality across all substance categories. Key clinical benefits include:

• Prevention of acute liver failure: N-acetylcysteine given within 8 hours of paracetamol ingestion prevents hepatotoxicity in virtually 100% of cases. Delayed treatment (8–24 hours) retains significant hepatoprotective benefit but outcomes worsen progressively beyond this window.
• Reversal of opioid-induced respiratory arrest: Naloxone restores adequate ventilation within minutes, preventing hypoxic brain injury and death from opioid overdose. Community naloxone programmes (take-home naloxone) have demonstrably reduced overdose mortality in high-incidence areas.
• Prevention of metabolic catastrophe: Early haemodialysis in methanol and ethylene glycol poisoning prevents permanent blindness and renal failure respectively — organ damage that is otherwise irreversible.
• Avoidance of cardiac toxicity: Early sodium bicarbonate therapy in TCA overdose prevents lethal dysrhythmias and cardiovascular collapse.
• Reduced length of stay: Risk-stratified management using validated nomograms and toxidrome-guided protocols allows safe early discharge of low-risk presentations, reducing unnecessary hospital resource utilisation.
• Psychological intervention: The emergency presentation offers a critical opportunity for suicide risk assessment and referral to mental health services, with evidence that brief intervention during hospitalisation reduces repeat self-harm episodes.

Poison centre consultation is associated with improved clinical outcomes, appropriate antidote use, and reduced unnecessary investigations. TOXBASE access by front-line nurses has been shown to reduce inappropriate emergency attendances for low-toxicity exposures.

Toxicological management carries specific procedure-related risks alongside complications of the poisoning itself:

• Activated charcoal aspiration: Pulmonary aspiration of activated charcoal during administration to obtunded patients causes aspiration pneumonitis and black endobronchial casts. Mandatory airway protection (cuffed endotracheal intubation) prior to charcoal administration in any patient with reduced consciousness.
• N-acetylcysteine infusion reactions: Anaphylactoid reactions (not IgE-mediated) occur in 10–20% of patients, typically during the first infusion bag — manifest as urticaria, flushing, wheeze, and rarely bronchospasm. Management: stop infusion, administer antihistamine, restart at slower rate. Adrenaline rarely required. Higher rates in patients with low plasma paracetamol levels.
• Flumazenil seizures: Precipitated seizures in BZD-dependent patients or those with TCA co-ingestion are the most dangerous complication of flumazenil use. These seizures may be refractory to standard anticonvulsants as the very antidote pathway is blocked.
• Naloxone acute withdrawal: Abrupt reversal of opioid effect precipitates acute withdrawal (severe agitation, vomiting, acute pulmonary oedema in susceptible patients). Careful titration to ventilation rather than wakefulness mitigates this risk.
• Delayed toxicity: Many substances have delayed peak toxicity — paracetamol hepatotoxicity peaks at 72–96 hours, amatoxin-induced liver failure appears 2–4 days post-ingestion, and colchicine cardiotoxicity occurs on day 2–4. Premature discharge based on early asymptomatic presentation risks catastrophic outcomes.
• Complications of haemodialysis: Include hypotension, access-site haemorrhage, electrolyte shifts, and air embolism. Lithium rebounds after cessation of HD requires extended dialysis sessions.

Post-acute monitoring requirements vary substantially by substance and severity. Mandatory follow-up considerations include:

• Paracetamol overdose: Repeat LFTs, INR, creatinine and acid-base at 24, 36, and 48 hours. Referral to hepatology or liver transplant unit if INR >2.0 at 24 hours, or rising bilirubin/creatinine. Use Kings College Criteria to assess prognosis and transplant listing.
• Opioid overdose: Extended observation (minimum 4–6 hours after last naloxone dose) for long-acting opioids. Buprenorphine/naloxone (Suboxone) or methadone maintenance referral as part of a harm-reduction plan. Take-home naloxone prescription at discharge.
• Salicylate toxicity: Serial salicylate levels until downtrending, with urinary alkalinisation (urinary pH 7.5–8.5) maintained until level <300 mg/L. Late redistribution from tissues can cause rebound toxicity.
• TCA overdose: Cardiac monitoring for minimum 6 hours in asymptomatic patients with normal ECG. Any QRS widening mandates admission to a monitored bed until ECG normalisation.
• Mental health follow-up: All patients with intentional self-poisoning require formal psychiatric assessment before discharge, with documented safety plan, crisis line numbers, and referral to community mental health or crisis team. GP notification is mandatory.
• Occupational/environmental exposure: Liaison with occupational health, environmental health officers, and NPIS for workplace exposures. Biological monitoring (e.g., blood lead levels, urinary arsenic) for occupational heavy metal exposures.

The economic burden of acute poisoning is substantial and determined by several factors:

• Severity and length of stay: An uncomplicated paracetamol overdose treated with a standard NAC regimen may require 24-hour admission. Severe toxicity requiring ICU admission, haemodialysis, or liver transplantation carries costs exceeding £50,000–£200,000 per episode in UK NHS settings.
• Antidote costs: N-acetylcysteine is inexpensive (under £20 per treatment course). Hydroxocobalamin for cyanide poisoning costs £700–£1,000 per vial. Digoxin-specific antibody fragments (Digibind/DigiFab) cost £700–£3,500 per treatment. Fomepizole (4-MP) for methanol/ethylene glycol — where used instead of ethanol — costs £2,000–£5,000.
• Haemodialysis: Each session costs approximately £400–£600 in NHS settings; methanol poisoning may require multiple extended sessions.
• Hyperbaric oxygen therapy: A single HBO session costs £500–£1,500; multi-session treatment for CO poisoning adds considerably to total costs.
• Psychiatric liaison and mental health: Specialist psychiatric assessment and inpatient mental health care represent a significant component of total poisoning-related costs.
• Private/international patients: In private hospitals or international treatment settings, costs are higher. Travel medical insurance strongly recommended. Some countries (India, Thailand, Turkey) offer competitive pricing for medical management — typically 30–60% less than Western rates for equivalent ICU-level care.

Prevention programmes — public education, medication blister packaging (reduces paracetamol overdose lethality), naloxone community distribution, and workplace chemical safety — are highly cost-effective compared to acute treatment costs.

While emergency medical management is not optional in significant poisoning, several adjunct and alternative considerations inform the overall care pathway:

• Ethanol therapy for methanol/ethylene glycol: Oral or intravenous ethanol competes with methanol and ethylene glycol for alcohol dehydrogenase, blocking formation of toxic metabolites (formate, oxalate). Largely replaced by fomepizole (4-methylpyrazole) in high-income settings due to easier administration, but ethanol remains widely used in resource-limited settings as a cost-effective alternative.
• Urinary alkalinisation (sodium bicarbonate infusion): For salicylate and methotrexate — promotes ion trapping in urine, accelerating renal elimination. Used before or instead of haemodialysis in mild-to-moderate salicylate toxicity.
• Lipid emulsion therapy (Intralipid): 20% intralipid has evidence supporting use in refractory local anaesthetic systemic toxicity (LAST) and as a "lipid sink" for highly lipid-soluble cardiac toxins (verapamil, TCA). AACT guidelines endorse use when conventional resuscitation is failing.
• Liver support systems: MARS (Molecular Adsorbent Recirculating System) and Prometheus systems provide extracorporeal liver support in acute liver failure from paracetamol or mushroom poisoning as a bridge to transplantation or spontaneous recovery.
• Complementary approaches: There is no evidence supporting traditional remedies, herbal preparations, or homeopathy in acute poisoning management. These approaches should not be used instead of or before conventional emergency treatment. Milk, egg white, or induced vomiting are not recommended and may cause harm.
• Prevention and harm reduction: Naloxone take-home programmes, needle exchange services, safer drug use education, and medication pack size restrictions (paracetamol limited to 32 tablets OTC in UK) represent public health alternatives to acute treatment that demonstrably reduce morbidity and mortality at population level.